

28 October 2026

Sydney, Australia

Securities Purchase Plan Results

Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, today announces the close of its Securities Purchase Plan (SPP) having raised AU\$0.73 million before costs.

The SPP offered eligible CDI holders, registered on the Record Date, the opportunity to subscribe for new fully paid CDIs up to a maximum value of \$30,000 per eligible CDI holder.

Nyrada will issue 1,174,004 new CDIs on 30 October 2026 at an issue price of \$0.620 per CDI. New CDIs will rank equally with existing CDIs. ASX trading in the new CDIs will commence on 2 November 2026.

SPP participants will also receive three (3) options for every four (4) CDIs subscribed for in the SPP, with each option having an exercise price of AU\$0.93 and an exercise period ending on 25 September 2028 (Attaching Option), being a total of 880,513 Attaching Options. Each Attaching Option gives the holder the right to receive one (1) CDI and one (1) Piggyback Option upon exercise and payment of the exercise price.

Further, in respect of the Placement announced on 21 September 2026 and issued on 25 September 2026, 8,316,537 Attaching Options will also be issued.

A total of 9,197,050 Attaching Options will accordingly be issued on 30 October 2026. The Company will be seeking the quotation of the Attaching Options, subject to the meeting the quotation requirements under Listing Rules.

Each Piggyback Option gives the holder the right to receive one (1) CDI upon exercise and payment of the exercise price. Notwithstanding, when an Attaching Option is exercised, no Piggyback Options will be granted until the exercise period for the Attaching Options has expired.

Nyrada Chair, John Moore, expressed his gratitude to CDI holders, stating: "We sincerely thank all CDI holders for their support. This SPP was designed to give our valued holders the chance to participate in the Company's capital raise on the same terms as the placement participants.

"Nyrada is at an important stage in its journey and is well-funded to advance the development of Xolatryp®."

-ENDS-



About Xolatryp®

Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca^{2+} entry related to multiple disease pathologies.

[A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics has been successfully completed](#) and a [Phase IIa clinical trial](#) has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI).

Key Links:

Cardioprotection

- PROTECT-MI website - <https://www.protect-mi.com>
- PROTECT-MI NIH Entry - <https://bit.ly/4cB2fF9>
- FDA IND Feedback - <https://bit.ly/4zyu9dZ>
- Phase IIa factsheet - <https://bit.ly/4bcDIKj>
- Preclinical cardioprotection study 1a - <https://bit.ly/4sigwMZ>
- Preclinical cardioprotection study 1b - <https://bit.ly/4rmOsXn>
- Preclinical cardioprotection study 2 - <https://bit.ly/40jHpUg>

Oncology

- Preclinical cardiomyopathy study - <https://bit.ly/4yR9BgD>
- Preclinical cardiomyopathy pilot study - <https://bit.ly/4xJH3Fj>
- Preclinical anti-tumour study - <https://bit.ly/49rWOa0>

Neuroprotection

- Preclinical traumatic brain injury study - <https://bit.ly/40fhrRT>
- Preclinical stroke study - <https://bit.ly/4sygHmH>

Foundations

- US Patent Grant - <https://bit.ly/4yUqMyf>
- Phase I results - <https://bit.ly/3NtOGzH>
- Preclinical mitochondria stabilisation study - <https://bit.ly/4yiZUHa>
- GLP study results - <https://bit.ly/4d8VYkX>
- CSANZ Conference Poster - <https://bit.ly/4A9ROmf>

Corporate

- Latest presentation slides - <https://bit.ly/46FM9Xq>



About Nyrada Inc.

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.

Investor & Media Enquiries:

Dimitri Burshtein

T: 0491 789 391

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.